

INDICATION: DUPIXENT is a prescription medicine used with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and children 12 years of age and older whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with CRSwNP under 12 years of age.

Please see Important Safety Information throughout and full Prescribing Information including Patient Information.

DUPIXENT® (dupilumab) Injection 300mg



DUPIXENT® (dupilumab) GOES BEYOND

Discover **DUPIXENT**, the **first FDA-approved biologic treatment** for chronic rhinosinusitis with nasal polyps.

- It goes beyond just treating nasal polyps by helping block two of the key sources of underlying inflammation that may cause them.

It has already been used to treat over

85,000 patients*
who suffer from nasal polyps.

See how DUPIXENT may be able to help you too.

*Data on file, Sanofi US. IQVIA Sanofi Integrated DUPIXENT Platform; data through February 2026.

IMPORTANT SAFETY INFORMATION: Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT.

Please see additional Important Safety Information throughout and full Prescribing Information including Patient Information.

DUPIXENT®
(dupilumab) Injection 300mg

GO BEYOND
WITH LESS NASAL POLYPS

DUPIXENT is an alternative treatment to nasal polyp surgery that can:

- Shrink nasal polyps
- Help you breathe better
- Reduce congestion in as little as 2 days*
- Improve smell in as little as 3 days*
- Significantly reduce the need for oral steroids†‡

*Individual results may vary.

†Don't stop taking your corticosteroid medicine unless instructed by your doctor.

‡In clinical studies in adults evaluating DUPIXENT 300 mg + standard of care (SOC) vs placebo + SOC, 76% fewer patients taking DUPIXENT required oral/injected steroids or surgery.

DUPIXENT had a demonstrated efficacy and safety profile in clinical trials of adult patients and is approved for CRSwNP patients aged 12 years and older.





IMPORTANT SAFETY INFORMATION: Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

- have eye problems.
- have a parasitic (helminth) infection.
- are scheduled to receive any vaccinations. You should not receive a "live vaccine" right before and during treatment with DUPIXENT.

Please see additional Important Safety Information throughout and full Prescribing Information including Patient Information.



GO BEYOND
AND DO YOU

In clinical studies, adult patients on DUPIXENT saw an improvement in symptoms, which included, but were not limited to:

- Nasal blockage
- Facial pain/ pressure
- Difficulty falling asleep
- Fatigue
- Decreased sense of smell and taste

The relationship between DUPIXENT and its effect on individual symptoms was studied by a multi-symptom questionnaire but not definitively proven. Ask your doctor how DUPIXENT may help.

The most common side effects in patients with CRSwNP include injection site reactions; eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, and blurred vision; high count of a certain white blood cell (eosinophilia); stomach problems (gastritis); joint pain (arthralgia); trouble sleeping (insomnia); and toothache.

IMPORTANT SAFETY INFORMATION: Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you (cont'd):

- are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby.
  - A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby
- are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.

Please see additional Important Safety Information throughout and full Prescribing Information including Patient Information.

DUPIXENT® (dupilumab) Injection 300mg

BEYOND
TREATING SYMPTOMS

A CAUSE OF CHRONIC NASAL POLYPS

Underlying inflammation may be a source of chronic nasal polyps, which can be present even when you aren't experiencing symptoms.

HOW DUPIXENT GOES BEYOND

DUPIXENT is a biologic that helps block two of the key sources of underlying inflammation that may cause chronic nasal polyps. It can continuously work to shrink them down.

IMPORTANT SAFETY INFORMATION: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines or if you have CRSwNP and asthma and use an asthma medicine. **Do not** change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back.



IMPORTANT SAFETY INFORMATION: DUPIXENT can cause serious side effects, including:

- **Allergic reactions. DUPIXENT can cause allergic reactions, including skin reactions, that can sometimes be severe.** Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue, or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, skin rash, including rash that looks like a bullseye or painful red or blue bumps under the skin, general ill feeling, itching, swollen lymph nodes, nausea or vomiting, joint pain, or cramps in your stomach area.
- **Eye problems.** Tell your healthcare provider right away if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an eye exam if needed.

Please see additional Important Safety Information throughout and full Prescribing Information including Patient Information.

DUPIXENT® (dupilumab) Injection 300mg

BREAK THE CYCLE OF SURGERY

Take action against chronic inflammation in a completely different way.

Surgery removes nasal polyps, but it may not treat an underlying cause—which can allow them to grow back. DUPIXENT can help shrink your nasal polyps, even if you've never had nasal polyp surgery.

Some nasal polyp patients have polyp regrowth after surgery, with **35% of patients having polyps grow back after only 6 months**.

83% FEWER PATIENTS ON DUPIXENT REQUIRED NASAL POLYP SURGERY*

*Compared to placebo + standard of care in adult patients.

In clinical trials with adult patients, many patients on DUPIXENT who had a prior surgery saw a reduction in need for another one.

IMPORTANT SAFETY INFORMATION: DUPIXENT can cause serious side effects, including (cont'd):

- **Inflammation of your blood vessels.** Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. Tell your healthcare provider right away if you get: rash, chest pain, worsening shortness of breath, brown or dark colored urine, persistent fever, or a feeling of pins and needles or numbness of your arms or legs.



IMPORTANT SAFETY INFORMATION: DUPIXENT can cause serious side effects, including (cont'd):

- **Joint aches and pain.** Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.

The most common side effects in patients with CRSwNP include injection site reactions; eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, and blurred vision; high count of a certain white blood cell (eosinophilia); stomach problems (gastritis); joint pain (arthralgia); trouble sleeping (insomnia); and toothache.

Please see additional Important Safety Information throughout and full Prescribing Information including Patient Information.



IMPORTANT SAFETY INFORMATION: Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

LESS CONGESTION
COULD BE A CONVERSATION AWAY

Still struggling with chronic nasal polyp symptoms? Talking to your doctor is the first step on your treatment journey. Here are the three topics you can bring up with your doctor to figure out a treatment plan that will work for you.

1. **How often are chronic nasal polyps getting in the way of daily activities?**

   ◯ Daily ◯ Weekly ◯ Monthly

2. **Which chronic nasal polyp symptoms bother you the most?**

   _____

   _____

3. **What are you most looking forward to once your symptoms are under control?**

   _____

   _____

IMPORTANT SAFETY INFORMATION: Use DUPIXENT exactly as prescribed by your healthcare provider. It's an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. **Do not** try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it's recommended DUPIXENT be administered by or under supervision of an adult.

Please see additional Important Safety Information throughout and full Prescribing Information including Patient Information.

DUPIXENT® (dupilumab) Injection 300mg

HAS YOUR DOCTOR PRESCRIBED DUPIXENT® (dupilumab)?

Your healthcare provider is your best resource for information about DUPIXENT and should be your primary point of contact throughout your treatment journey.

Click here
to take advantage of our injection resources and supplemental training videos.

WHAT CAN *DUPIXENT MyWay®* DO FOR YOU?

Enrolling in *DUPIXENT MyWay* can help ensure you receive DUPIXENT (dupilumab) as quickly as possible and receive additional support along your treatment journey.

Click here
to sign up to speak with a real DUPIXENT patient about their journey.

PAY AS LITTLE AS $0*

Eligible patients covered by commercial health insurance may pay as little as $0* in copay per fill of DUPIXENT through the *DUPIXENT MyWay* Copay Card Program.



99% OF COMMERCIALLY INSURED PATIENTS IN THE US ARE COVERED FOR DUPIXENT

*Subject to the program maximum per patient per calendar year. Approval is not guaranteed. **THIS IS NOT INSURANCE.** Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs, including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed, or restricted. *DUPIXENT MyWay* reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients' out-of-pocket costs. The program is intended to help patients afford DUPIXENT. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program, such as "accumulator adjustment" or "copay maximizer". These plans may also affect the program terms and eligibility. Additional terms and conditions apply.



*Data on file, Sanofi US. IQVIA weekly NSOB; data through March 2026.

IMPORTANT SAFETY INFORMATION: Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT.

Please see additional Important Safety Information throughout and full Prescribing Information including Patient Information.

Health information contained herein is provided for general educational purposes only. Your doctor is the single best source of information regarding your health. Please consult your doctor if you have any questions about your health or treatment.

©2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
DUPIXENT® and *DUPIXENT MyWay®* are registered trademarks of Sanofi Biotechnology.
US.DUP.26.10.0216 11/2026

sanofi | REGENERON®